Pre-made Naratuximab biosimilar ( Whole mAb ADC, anti-CD37 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-364
Anti-CD37 therapeutic antibody (Pre-made Naratuximab biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Naratuximab emtansine | IMGN529 (K7153A) | Debio 1562 | Drug Description. ... The investigational drug is in clinical trials for the potential treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia, B-Cell Lymphomas. CD37, a transmembrane glycoprotein, is overexpressed in B-cell malignancies.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-CD37 therapeutic antibody (Pre-made Naratuximab biosimilar,Whole mAb ADC)|
|Format||Whole mAb ADC|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||ImmunoGen;Chronic lymphocytic leukaemia|
|Conditions Active||Diffuse large B cell lymphoma;Non-Hodgkin's lymphoma|
|Conditions Discontinued||Chronic lymphocytic leukaemia|